

## **TRANSPLENTAL PASSAGE OF FLUORIDE IN PREGNANT POLISH WOMEN ASSESSED ON THE BASIS OF FLUORIDE CONCENTRATIONS IN MATERNAL AND CORD BLOOD PLASMA**

J Opydo-Szymaczek,<sup>a</sup> M Borysewicz-Lewicka<sup>a</sup>

Poznan, Poland

**SUMMARY:** The aim of this study was to evaluate placental transfer of fluoride (F) in 30 pregnant women at the time of giving birth, who were living in Poznan, Poland, where the F concentration in the drinking water ranges from 0.4 to 0.8 mg/L. F concentrations of maternal and umbilical venous cord blood plasma were determined in samples drawn at delivery. The mean concentration of F in maternal plasma was significantly higher than in venous cord plasma (3.54 vs. 2.89  $\mu\text{mol/L}$ , respectively), and both values were similar to those previously documented in pregnant women taking prenatal F supplements. The results confirm that F readily passes through the placenta and that prenatal F supplements, still recommended by some authors, are contraindicated in this population.

Keywords: Fluoride exposure; Placental F transfer; Plasma fluoride; Poznan, Poland; Pregnant women.

### **INTRODUCTION**

Results of studies comparing F levels in maternal and umbilical cord venous blood plasma,<sup>1-8</sup> as well as intra-uterine studies,<sup>9</sup> prove that F passes through the placenta. Whether and to what extent the placenta can act as a filter and limit transmission of F to fetal circulation remain matters of debate,<sup>1,3,4</sup> and is therefore an important question in the discussion of prenatal F supplementation. Moreover, despite many unfavorable reports and opinions, many dental authorities still recommend prenatal F tablets for pregnant women to provide what some regard as appropriate dosages of F for the primary tooth buds.<sup>10-14</sup>

Our recent study of urinary fluoride levels of pregnant women in Poznan, Poland, where the F level in the drinking water is 0.4–0.8 mg/L, revealed that total F exposure of the examined population is relatively high and comparable to the level observed in areas with fluoridated water.<sup>15</sup> The aim of the present study was to assess F concentrations in maternal and umbilical cord venous blood plasma during delivery in the same group of pregnant women.

### **MATERIALS AND METHODS**

The subjects of the study were 30 healthy pregnant women, 22–34 years old, who, during the pregnancy and delivery, were under medical supervision of physicians from the Department of Perinatology of the University of Medical Sciences in Poznan, Poland. These same women also participated in our recent study of urinary F levels during their pregnancies<sup>15</sup> and were recruited by voluntary consent in the Gynecology and Obstetrics Hospital in Poznan with approval by the Ethics Committee of the University.

---

<sup>a</sup>For Correspondence: J Opydo-Szymaczek, Department of Pediatric Dentistry, Poznan University of Medical Sciences, Bukowska 70, 60-812 Poznan, Poland. E-mail: jopydo@am.poznan.pl

All women were hospitalized during the time of delivery. The duration of pregnancy, calculated from the date of the last menstruation, ranged from 38 to 41 weeks. Seven women delivered by caesarian section under local subarachnoid anesthesia, and the others delivered vaginally by spontaneous labor. All were informed of the purpose of the study and gave their consent for the blood sampling.

Seven-mL samples of venous cord blood and maternal blood were drawn at delivery into disposable polystyrene tubes containing heparin as an anticoagulant. The samples were centrifuged, and the separated plasma was stored at  $-20^{\circ}\text{C}$  for 1 to 4 weeks. F analyses were conducted at pH 5.0 adjusted by TISAB III buffer with an Orion Model 96-09 F ion selective electrode in the standardized laboratory of the Department of Biochemistry and Chemistry of the Pomeranian Medical University in Szczecin. Measurements were performed using the convenient addition method<sup>16</sup> capable of determining F concentrations as low as  $2.5\ \mu\text{g/L}$  ( $= 0.0025\ \text{mg/L}$  or  $0.13\ \mu\text{M}$ ).

The data were analyzed statistically using Statistica Version 5 for Windows XP Professional Version 5.1 with significance taken as  $p < 0.05$ .

## RESULTS

Maternal and umbilical venous cord plasma F (MF and CF, respectively) and the CF/MF ratio are presented in Table 1. The data were divided into two subgroups according to the value of the CF/MF ratio ( $\geq 1.0$  or  $< 1.0$ ).

The MF concentration ranged from 2.40 to 6.80  $\mu\text{mol/L}$  (mean value  $3.54\ \mu\text{mol/L} = 0.0673\ \text{mg/L}$ ), and the CF concentration ranged from 2.20 to 4.10  $\mu\text{mol/L}$  (mean value  $2.89\ \mu\text{mol/L} = 0.0549\ \text{mg/L}$ ), which are significantly different.

The ratio of the CF to MF concentration ranged from 0.427 to 1.20 (mean 0.869). In one case it equaled 1.0, and in four cases it exceeded 1.0.

**Table 1.** Maternal (MF) and cord (CF) blood plasma concentration ( $\mu\text{mol F/L}$ ) and CF/MF ratio in two subgroups of pregnant women divided according to the CF/MF value

Group of women	No. of cases		MF	CF	CF/MF
CF/MF less than 1.0	25	Mean	3.69	2.84	0.822
		Median	3.00	2.80	0.871
		Min	2.40	2.20	0.427
		Max	6.80	3.50	0.971
		SD	1.24	0.38	0.166
		CF/MF greater than or equal to 1.0	5	Mean	2.80
Median	2.50			2.90	1.108
Min	2.40			2.60	1.000
Max	3.70			4.10	1.200
SD	0.54			0.59	0.084
Total	30			Mean	3.54
		Median	3.00	2.80	0.919
		Min	2.40	2.20	0.427
		Max	6.80	4.10	1.200
		SD	1.20	0.42	0.187

\* $p < 0.001$  compared with MF.

Pearson correlation coefficients ( $r$ ) and coefficients of determinations ( $r^2$ ) between MF and CF, and between CF/MF ratio and maternal age are listed in Table 2. A positive correlation was found between MF and CF concentration ( $r = 0.45$ ,  $p < 0.02$ ). There was no significant correlation between the mother's age and the CF MF ratio ( $p = 0.41$ ).

**Table 2.** Correlation between MF and CF levels and between maternal age and CF/MF ratio

	MF, CF	Maternal age, CF/MF
Pearson correlation coefficient, $r$	0.45*	0.16 <sup>†</sup>
Coefficient of determination, $r^2$	0.20	0.02

\* $p < 0.02$ , <sup>†</sup> $p = 0.41$ .

## DISCUSSION

Various authors, in different countries, who have measured F concentrations in the blood plasma and serum of pregnant women residing in areas with a level of F in drinking water  $\leq 0.5$  mg/L, report mean MF values of 1.46  $\mu\text{mol/L}$  (0.0277 mg/L),<sup>1</sup> 1.79  $\mu\text{mol/L}$  (0.0340 mg/L),<sup>4</sup> 1.37  $\mu\text{mol/L}$  (0.0123 mg/L),<sup>5</sup> and 1.58  $\mu\text{mol/L}$  (0.0300 mg/L).<sup>7</sup> In pregnant Polish women, Chlubek et al. found up to 4.25  $\mu\text{mol/L}$  (0.0808 mg/L).<sup>2</sup> Despite similar content of F in the drinking water, the reported values vary widely, which might be attributed to the different total F exposures of examined populations. Today there are many other sources of F in the environment, and, as stated recently by the US National Academy of Sciences/National Research Council, "... it is no longer feasible to estimate with reasonable accuracy the level of F exposure simply on the basis of concentration in drinking water supply."<sup>17</sup>

The study by Caldera et al.<sup>1</sup> revealed that the mean CF concentration of pregnant women taking F supplements (1.5 mg daily) residing in an area with about 0.5 mg F/L in the drinking water was 3.07  $\mu\text{mol/L}$  (0.0583 mg/L), which is comparable to the value of 2.89  $\mu\text{mol/L}$  (0.0549 mg/L) determined in our study group. Similarly, the intra-uterine study by Forestier et al.<sup>9</sup> showed that mean fetal blood serum F levels in mothers who had taken F tablets (2.212 mg NaF/day) equaled 2.6  $\mu\text{mol/L}$  (0.0494 mg/L).

Results of our work indicate that CF concentrations reach, on average, 87% of those in maternal blood. Most authors have observed a similar pattern of results. The mean value of the proportion reported by other authors ranges from 60% in the study of Shimonovitz et al.<sup>7</sup> and the study of Gupta et al.<sup>3</sup>, through 77% in Polish women examined by Chlubek et al.,<sup>2</sup> 75% in the group examined by Shen and Taves,<sup>6</sup> 84% in the study of Ron et al.,<sup>5</sup> and 91% in women examined by Montherrat-Carret et al.<sup>4</sup> The difference between the MF and CF levels might suggest that the placenta acts as a partial filter for F. A possible explanation of the F loss during transmission from maternal to fetal circulation has been presented by Chlubek et al.,<sup>18</sup> whose study revealed that F can be accumulated in the marginal parts of the placenta as a result of higher concentrations of calcium in those areas.

However, as already noted, in four cases in our study MF levels were lower than and in one case equaled CF levels. Caldera et al.,<sup>1</sup> who measured MF and CF levels in 91 women, obtained such results in most subjects of their study. Only a

few of the neonates had a CF level lower than the MF level. These authors note that MF and CF levels depend on the intake and the movement of F between plasma and skeleton. Instead of discussing a passive or active role of the placenta, they propose the concept of a maternal-fetal-amniotic pool that regulates maternal and fetal F plasma levels according to the F intake. Moreover, haemodynamic and haematochemical variations at the time of delivery also appear to affect CF levels, as suggested by Brambilla et al.<sup>10</sup> This is probably why only about 20% of the variance in CF levels in our work can be explained by variations in MF levels (Pearson correlation coefficient = 0.45 with the coefficient of determination = 0.20).

It has been suggested that higher maternal age can be related to generally lower transplacental transfer due to lower uterine blood flow at the placental bed.<sup>2,5</sup> Our research, however, does not confirm this view since no significant correlation was found between the mother's age and the CF/MF ratio. However, it might be connected with the wider age span of women in the studies by Ron et al.<sup>5</sup> and Chlubek et al.<sup>2</sup> (aged 18–39 and 17–38 years, respectively) compared to that of our group (aged 22–34).

It is noteworthy that results of the recent studies by Leverett et al.<sup>19</sup> and Fonteles et al.<sup>20</sup> have not supported the hypothesis that the use of fluoride supplements by pregnant women benefit their offspring. Moreover, as noted recently,<sup>21</sup> modern research provides little support for recommendation of either prenatal or postnatal F supplements. In spite of these controversies, prenatal fluoride supplementation has been a standard practice for years in some countries, including Poland.<sup>10-14</sup>

Our data indicate that in an area where the drinking water F concentration ranges from 0.4 to 0.8 mg/L, fluoride levels in maternal and cord blood plasma are comparable to those documented in patients from other areas who are taking F supplements (1.5 mg/daily). Thus, the use of additional F supplements is particularly contraindicated in this population. This practice could result in a further increase of F exposure to the fetus, which raises concerns in view of the potential negative effects of excessive amounts of F on fetal development.<sup>22-24</sup>

#### ACKNOWLEDGEMENTS

This study was supported by the Polish State Committee for Scientific Research E01922. We also wish to thank Professor Dariusz Chlubek for his expert support.

#### REFERENCES

- 1 Caldera R, Chavinie J, Fermanian J, Tortrat D, Laurent AM. Maternal-fetal transfer of fluoride in pregnant women. *Biol Neonate* 1988;54(5):263-9.
- 2 Chlubek D, Mokrzynski S, Machoy Z, Samujlo D, Wegrzynowski J. Fluoride concentration in mother and fetus. I. Placental transport of fluoride. *Ginekol Pol* 1994;65(11):611-5.
- 3 Gupta S, Seth AK, Gupta A, Gavane AG. Transplacental passage of fluorides. *J Pediatr* 1993;123(1):139-41.
- 4 Montherrat-Carret L, Perrat-Mabilon B, Barbey E, Bouloc R, Boivin G, Michelet A, et al. Chemical and X-Ray analysis of fluoride, phosphorus and calcium in human foetal blood and hard tissues. *Arch Oral Biol* 1996;41(12):1169-78.
- 5 Ron M, Singer L, Menczel J, Kidroni G. Fluoride concentration in amniotic fluid and fetal cord and maternal plasma. *Eur J Obstet Gynecol Reprod Biol* 1986;21(4):213-18.

- 50 Research report Transplacental passage of fluoride in pregnant Polish women assessed by 50  
Fluoride 40(1)46–50  
January-March 2007 maternal and cord blood plasma F  
Opydo-Szymaczek, Borysewicz-Lewicka
- 6 Shen YW, Taves DR. Fluoride concentrations in the human placenta and maternal cord blood. *Am J Obstet Gynecol* 1974;119(2):205-7.
  - 7 Shimonovitz S, Patz D, Ever-Hadani P, Singer L, Zacut D, Kidroni G, et al. Umbilical cord fluoride serum levels may not reflect fetal fluoride status. *J Perinat Med* 1995;23(4): 279-82.
  - 8 Malhotra A, Tewari A, Chawla HS, Gauba K, Dhall K. Placental transfer of fluoride in pregnant women consuming optimum fluoride in drinking water. *J Indian Soc Pedod Prev Dent* 1993;11(1):1-3.
  - 9 Forestier F, Daffos F, Said R, Brunet CM, Guillaume PN. The passage of fluoride across the placenta. An intra-uterine study. *J Gynecol Obstet Biol Reprod* 1990;19(2):171-5.
  - 10 Brambilla E, Felloni A, Gagliani M, Malerba A, Garcia-Godoy F, Strohmenger L. Caries prevention during pregnancy: results of a 30-month study. *Am Dent Assoc* 1998;129(10):1372-4.
  - 11 Brambilla E, Belluomo G, Malerba A, Buscaglia M, Strohmenger L. Oral administration of fluoride in pregnant women and the relation between concentration in maternal plasma and in amniotic fluid. *Arch Oral Biol* 1994;39(11):991-4.
  - 12 Glenn FB, Glenn WD, Burdi A R. Prenatal fluoride for growth and development: Part X. *J Dent Child* 1997;64(5):317-21.
  - 13 Glenn FB, Glenn WD. Optimum dosage for prenatal fluoride tablet supplementation: Part IX. *J Dent Child* 1987;54(6):445-50.
  - 14 Losso EM, Ramalho GM. Evaluation of Prenatal Fluoride Supplement Prescription in Curitiba and Metropolitan Region. *Rev Bras Ginecol Obstet* 2001;23(6):391-6.
  - 15 Opydo-Szymaczek J, Borysewicz-Lewicka M. Urinary fluoride levels for assessment of fluoride exposure of pregnant women in Poznan, Poland. *Fluoride* 2005;38(4):312-7.
  - 16 Fuchs C, Dorn D, Fuchs CA, Henning H, McIntosh C, Scheler F, et al. Fluoride determination in plasma by ion selective electrodes: a simplified method for the clinical laboratory. *Clin Chim Acta* 1975;60(2):157-67.
  - 17 Committee on Toxicology, National Research Council of the National Academies. *Health Effects of Ingested Fluoride*. Washington, DC: National Academy of Sciences Press;1993.
  - 18 Chlubek D, Poreba R, Machalinski B. Fluoride and calcium distribution in human placenta. *Fluoride* 1998;31(3):131-6.
  - 19 Leverett DH, Adair SM, Vaughan BW, Proskin HM, Moss ME. Randomized clinical trial of the effect of prenatal fluoride supplements in preventing dental caries. *Caries Res* 1997; 31(3):174-9.
  - 20 Sa Roriz Fonteles C, Zero DT, Moss ME, Fu J. Fluoride Concentrations in Enamel and Dentin of Primary Teeth after Pre- and Postnatal Fluoride Exposure. *Caries Res* 2005; 39(6):505-8.
  - 21 Burgstahler AW. Fluoridated bottled water [editorial]. *Fluoride* 2006;39(4):252–4.
  - 22 Mullenix PJ, Denbesten PK, Schunior A, Kernan WJ. Neurotoxicity of sodium fluoride in rats. *Neurotoxicol Teratol* 1995;17(2):169–77.
  - 23 Du L. The effect of fluorine on the developing human brain. *Zhonghua Bing Li Xue Za Zhi* 1992;21(4):218-20.
  - 24 Shi J, Dai G, Zhang Z. Relationship between bone fluoride content, pathological change in bone of aborted fetuses and maternal fluoride level. *Zhonghua Yu Fang Yi Xue Za Zhi* 1995;29(2):103-5.